Durvi Patel, MD , who integrates this advanced treatment into a comprehensive wellness program
The class of medications that include semaglutide are not recommended for women who are pregnant or trying to become pregnant
In clinical trials, patients taking semaglutide GLP-1 over 68 weeks have been able to achieve weight loss of up to 10 to 20% of their total body weight
GLP-1 Receptor Activation Suppresses appetite and slows gastric emptying Improves insulin sensitivity Reduces fat storage 2
Tirzepatide occupies the middle ground Tirzepatide, a dual GIP/GLP-1 receptor agonist, showed a reporting odds ratio of 1.73, elevated but lower than semaglutide
About 50% of patients on ADMs used metformin only, with over 33% using insulin